Toyota|$17.95 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.13 (¥3,958)+0.56%▲ (in JPY terms)
SoftBank|$28.45 (¥4,481)-5.96%▼ (in JPY terms)
MUFG|$21.88 (¥3,447)-0.49%▼ (in JPY terms)
Keyence|$495.18 (¥78,000)+2.15%▲ (in JPY terms)
Nintendo|$52.62 (¥8,289)+1.61%▲ (in JPY terms)
NTT|$1.10 (¥173)+1.05%▲ (in JPY terms)
Takeda|$42.22 (¥6,651)+2.78%▲ (in JPY terms)
Tokyo Electron|$60.40 (¥9,514)-5.19%▼ (in JPY terms)
Recruit|$121.89 (¥19,200)+1.64%▲ (in JPY terms)
ITOCHU|$14.77 (¥2,327)+0.22%▲ (in JPY terms)
Honda|$11.34 (¥1,787)+1.33%▲ (in JPY terms)
Shin-Etsu|$37.87 (¥5,966)-0.73%▼ (in JPY terms)
Tokio Marine|$3.68 (¥579)+2.19%▲ (in JPY terms)
Fast Retailing|$478.29 (¥75,340)+2.09%▲ (in JPY terms)
Toyota|$17.95 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$25.13 (¥3,958)+0.56%▲ (in JPY terms)
SoftBank|$28.45 (¥4,481)-5.96%▼ (in JPY terms)
MUFG|$21.88 (¥3,447)-0.49%▼ (in JPY terms)
Keyence|$495.18 (¥78,000)+2.15%▲ (in JPY terms)
Nintendo|$52.62 (¥8,289)+1.61%▲ (in JPY terms)
NTT|$1.10 (¥173)+1.05%▲ (in JPY terms)
Takeda|$42.22 (¥6,651)+2.78%▲ (in JPY terms)
Tokyo Electron|$60.40 (¥9,514)-5.19%▼ (in JPY terms)
Recruit|$121.89 (¥19,200)+1.64%▲ (in JPY terms)
ITOCHU|$14.77 (¥2,327)+0.22%▲ (in JPY terms)
Honda|$11.34 (¥1,787)+1.33%▲ (in JPY terms)
Shin-Etsu|$37.87 (¥5,966)-0.73%▼ (in JPY terms)
Tokio Marine|$3.68 (¥579)+2.19%▲ (in JPY terms)
Fast Retailing|$478.29 (¥75,340)+2.09%▲ (in JPY terms)

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be installed in Iwata City, Shizuoka Prefecture, and a demonstration experiment will begin in April. Collaboration with the city will be carried out to verify its use in the event of a disaster.”

2026-03-02 Yamaha Motor Co.,Ltd. “March 2, 2026 [Corporate] A small water purification device will be in … 続きを読む

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate PADCEV™ (enfortumab vedotin) in cisplatin-eligible muscle-invasive bladder cancer were presented at the 2026 American Society of Clinical Oncology (ASCO GU) Annual Meeting.”

2026-03-02 Astellas Pharma Inc. “Results from the Phase III EV-304 trial of the antibody-drug conjugate … 続きを読む